Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective

International Journal of Cardiology
Zanfina AdemiDanny Liew

Abstract

In light of the Cardiovascular Outcomes for People using Anticoagulation Strategies (COMPASS) trial, our objective was to assess the cost-effectiveness, from the Australian healthcare perspective, of rivaroxaban in combination with aspirin versus aspirin alone for the prevention of recurrent cardiovascular disease among patients with stable atherosclerotic vascular disease. A Markov model was developed using input data from the COMPASS trial to predict the clinical course and costs of patients over a 20-year time-horizon. The model comprised of three health states: 'Alive without recurrent CVD', 'Alive after recurrent CVD' and 'Dead'. Costs were from the Australian public healthcare system perspective, and estimated from published sources, as were utility data. The costs of rivaroxaban were based on current acquisition prices on the Australian Pharmaceutical Benefits Schedule (PBS) and assumed as AUD$3.09/day. The main outcome of interest was the incremental cost-effectiveness ratio (ICER) in terms of cost per quality adjusted life year (QALY) gained, and cost per year of life saved (YoLS). Costs and benefits were discounted by 5.0% per year. Compared to aspirin alone, rivaroxaban plus aspirin was estimated to cost an additiona...Continue Reading

Citations

Jul 5, 2019·Expert Review of Clinical Pharmacology·Marcelo SanmartínCarmen Suarez Fernández
May 22, 2020·Expert Review of Clinical Pharmacology·José R González-JuanateyCarmen Suarez Fernández
Mar 14, 2019·European Journal of Preventive Cardiology·Marco De Carlo
Jan 27, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stephen J Nicholls, Adam J Nelson
Feb 6, 2020·Applied Health Economics and Health Policy·Jonathan Karnon, Brita Pekarsky
Jan 29, 2021·Cardiovascular Therapeutics·Muhammad AjmalTom Lassar
Jul 31, 2021·The American Journal of Cardiology·Peter LeeElla Zomer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.